Newsfeeds - Spark Newswire

8 minute read

IMUNON CEO Issues Letter To Shareholders; Reviews 2022 Accomplishments; Sets Forth 2023 Milestones And Long-Term Vision

Today, 3:29 PM

IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage biotechnology company, today announced that Dr. Corinne Le Goff, the company's president and chief executive officer, has issued the following letter to

IMNN

1 minute read

News

IMUNON Enters into Collaborative Research Agreement With The Wistar Institute’s Vaccine & Immunotherapy Center To Research IMUNON’s PLACCINE Vaccine Platform

By Benzinga Newsdesk

Today, 3:29 PM

IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug development company, and The Wistar Institute, a global leader in biomedical research located in the heart of University City, Philadelphia, through its Vaccine &

IMNN

16 minute read

Options

Stocks That Hit 52-Week Lows On Wednesday

By Benzinga Insights

Today, 3:29 PM

On Wednesday, 258 companies hit new 52-week lows.

ACB

17 minute read

Options

Stocks That Hit 52-Week Lows On Friday

By Benzinga Insights

Today, 3:29 PM

During Friday's trading, 293 companies set new 52-week lows.

ACEL

1 minute read

Watching Imunon, Zacks Small-Cap Research Sets $17 Price Valuation

By Benzinga Newsdesk

Today, 3:29 PM

https://s27.q4cdn.com/906368049/files/News/2022/Zacks_SCR_Research_11302022_IMNN_Bautz.pdf

IMNN

7 minute read

Options

Stocks That Hit 52-Week Lows On Wednesday

By Benzinga Insights

Today, 3:29 PM

During Wednesday's session, 107 stocks hit new 52-week lows.

AAP

1 minute read

Imunon, Inc. – Common Stock Q3 EPS $(0.87) Misses $(0.81) Estimate

By Benzinga Newsdesk

Today, 3:29 PM

Imunon, Inc. - Common Stock (NASDAQ:IMNN) reported quarterly losses of $(0.87) per share which missed the analyst consensus estimate of $(0.81) by 7.41 percent. This is a 3.33 percent increase over losses of $(0.90) per

IMNN

17 minute read

Earnings

Earnings Scheduled For November 14, 2022

By Benzinga Insights

Today, 3:29 PM

Companies Reporting Before The Bell • Opiant Pharma (NASDAQ:OPNT) is estimated to report quarterly loss at $1.49 per share on revenue of $3.68 million.

AAIC

2 minute read

News

IMUNON Enters Into Technology Evaluation Agreement With Acuitas Therapeutics To Evaluate IMUNON’s PLACCINE Plasmid DNA With Acuitas’ Lipid Nanoparticle Delivery System

By Benzinga Newsdesk

Today, 3:29 PM

IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug development company, and Acuitas Therapeutics, a private biotechnology company focused on the development of delivery systems for nucleic acid vaccines and therapeutics

IMNN

1 minute read